T1 at 1.5T and 3T compared with conventional T2*at 1.5T for cardiac siderosis by Alam, MH et al.
RESEARCH Open Access
T1 at 1.5T and 3T compared with
conventional T2* at 1.5T for cardiac
siderosis
Mohammed H. Alam1,2, Dominique Auger1,2, Gillian C. Smith1,2, Taigang He3, Vassilis Vassiliou1,2, A. John Baksi1,2,
Rick Wage1, Peter Drivas1, Yanqiu Feng4, David N. Firmin1,2 and Dudley J. Pennell1,2*
Abstract
Background: Myocardial black blood (BB) T2* relaxometry at 1.5T provides robust, reproducible and calibrated
non-invasive assessment of cardiac iron burden. In vitro data has shown that like T2*, novel native Modified
Look-Locker Inversion recovery (MOLLI) T1 shortens with increasing tissue iron. The relative merits of T1 and
T2* are largely unexplored. We compared the established 1.5T BB T2* technique against native T1 values at
1.5T and 3T in iron overload patients and in normal volunteers.
Methods: A total of 73 subjects (42 male) were recruited, comprising 20 healthy volunteers (controls) and 53 patients
(thalassemia major 22, sickle cell disease 9, hereditary hemochromatosis 9, other iron overload conditions 13). Single
mid-ventricular short axis slices were acquired for BB T2* at 1.5T and MOLLI T1 quantification at 1.5T and 3T.
Results: In healthy volunteers, median T1 was 1014 ms (full range 939–1059 ms) at 1.5T and modestly increased to
1165ms (full range 1056–1224 ms) at 3T. All patients with significant cardiac iron overload (1.5T T2* values <20 ms) had
T1 values <939 ms at 1.5T, and <1056 ms at 3T. Associations between T2* and T1 were found to be moderate
with y =377 · x0.282 at 1.5T (R2 = 0.717), and y =406 · x0.294 at 3T (R2 = 0.715). Measures of reproducibility of T1
appeared superior to T2*.
Conclusions: T1 mapping at 1.5T and at 3T can identify individuals with significant iron loading as defined by
the current gold standard T2* at 1.5T. However, there is significant scatter between results which may reflect
measurement error, but it is also possible that T1 interacts with T2*, or is differentially sensitive to aspects of iron
chemistry or other biology. Hurdles to clinical implementation of T1 include the lack of calibration against human
myocardial iron concentration, no demonstrated relation to cardiac outcomes, and variation in absolute T1 values
between scanners, which makes inter-centre comparisons difficult. The relative merits of T1 at 3T versus T2* at 3T
require further consideration.
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Background
Since a biological pathway for body iron surplus elimin-
ation is non-existent in humans, excess iron from gut
absorption or transfusion is stored in a stable hemosid-
erin form but once this storage capacity is exhausted
free iron can be left unbound. This free ferrous iron can
consequently catalyse cellular Fenton reactions and create
highly reactive hydroxyl radicals causing mitochondrial
dysfunction, [1] apoptosis and other cellular dysfunction
[2–4]. The most common cause of iron overload is the
transfusion dependent anaemias, in which cardiac iron
toxicity and contractile dysfunction can lead to heart
failure, arrhythmias and death [5, 6].
Cardiovascular magnetic resonance (CMR) T2* assess-
ment of myocardial iron burden at 1.5 Tesla (T) [7] plays
a crucial role in the early diagnosis and management
of patients with cardiac iron overload. [8] It has been
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validated against tissue iron concentration, [6, 9] and
there is a powerful relation between low T2* values
and future occurrence of heart failure [5]. It is used
worldwide with T2* values between centres having excel-
lent intercenter reproducibility, [10, 11] which allows
consistency of clinical management between centres and a
coherent approach to international guidelines [12]. Data
also shows that adoption of T2* CMR leads to a substan-
tial reduction in mortality in thalassaemia, which has been
attributed to the adoption of aggressive iron chelation
tailored to the heart before the onset of heart failure [13].
Against this background of substantial gains in clinical
management of transfusion dependent patients over the
last 15 years are new advances in hardware and software
technology. Increasingly 3T scanners are entering clinical
practice and these may offer advantages over conventional
1.5T magnets for iron burden quantification. Unfortunately,
3T CMR may suffer from increased artefacts making myo-
cardial T2* assessment challenging, particularly in patients
with a high degree of iron overload [14, 15]. Another more
recent advance is improved T1 mapping of the heart
by CMR. The Modified Look-Locker inversion recov-
ery (MOLLI) and its shortened version (ShMOLLI)
T1sequences (as well as a number of other sequence
variants) have now been used to assess myocardial T1.
Native T1 measurements have shown promise in the
assessment of diffuse interstitial fibrosis, [16] and may
help characterise myocardial infiltration in amyloidosis or
Anderson-Fabry disease [17, 18]. T1 measurements can
also be combined with gadolinium for quantification of
extracellular myocardial volume, which is promising for
clinical application for assessment of prognosis in heart
disease, [19, 20] and the measurement of myocardial amyl-
oid burden [21]. Native T1 has been shown to shorten
with increasing tissue iron concentration in vitro, [22] and
we recently reported the use of T1 in thalassaemia pa-
tients at 1.5T [23]. Therefore T1 is a credible technique to
evaluate for iron measurement. We further investigated
the relationship between native T1 at 1.5T and 3T against
the current gold standard technique of BB T2* at 1.5T in
normals and a spectrum of patients with transfusion
dependent anaemia.
Methods
Patients and study design
A total of 53 consecutive subjects were prospectively
recruited over a 6 month period from September 2012
to February 2013 from referrals for cardiac siderosis
screening or follow-up. A wide dynamic range of iron
loading was present in the patient group and was a real-
istic reflection of our population. Patients had successive
CMR scans at both 1.5T and at 3T. A group of 20 match-
ing healthy volunteers was also scanned. Exclusion criteria
were: 1) claustrophobia, 2) metallic implants or permanent
pacemaker and 3) inability to hold recumbent position
for >15 minutes. The study protocol was approved by
the local ethics committee, and all subjects gave written
informed consent.
Image acquisition
The BB T2* and MOLLI T1 CMR protocol was performed
on a 1.5T Sonata scanner, and then a 3T Skyra scanner
(both Siemens Medical Systems, Erlangen, Germany).
BB T2* acquisition
At 1.5T, a four-element cardiac phase-array coil was
used. After routine localizer acquisitions, an ECG gated
single breath hold multi-echo sequence was acquired at
a single mid-ventricular short axis slice with a 10 mm
thickness at eight separate echo times (2.6–16.74 ms, at
2.02 ms increments). The BB sequence used a flip angle
of 35°, a matrix of 128 X 256 pixels a field of view
(FOV) of 40 cm, repetition time of 20 ms between each
radiofrequency (RF) pulse and a sampling bandwidth of
810 Hz per pixel. Furthermore, for the black blood prep-
aration, double inversion pulses were applied at the R
wave trigger and the inversion time (TI) was set to ex-
tend into diastole.
Native MOLLI T1 acquisition
The sequence used for myocardial T1 evaluation has
been reported elsewhere [23]. In brief, non-selective in-
version recovery (IR) prepared ECG-synchronized Look-
Locker trains were performed in a 5 (3) 3 consecutive
pattern within a single breath-hold. Each of the three
trains started with a non-selective adiabatic inversion
pulse that used inversion times of 100, 180 and 260 ms,
after which multiple single-shot images were acquired in
successive heartbeats. Therefore, a set of 11 sources im-
ages with different inversion times were obtained. Data
acquisition consisted of a single mid-ventricular short
axis slice balanced steady-state free precession (SSFP)
sequence with acceleration factor 2. Bandwidth was
1085 Hz/pixel, base matrix of 256 pixels, flip angle 35°,
FoV 400 mm, TR = 3.9 ms, TE = 1.12 ms, voxel size 2.1 x
1.4 x 10 mm. At 3T, a 3 (3) five sequence was acquired.
The inversion times were 120, 200 and 280 ms. A set of
11 sources images with different inversion times were
obtained. Data acquisition consisted of a single mid-
ventricular short axis slice SSFP sequence with acceler-
ation factor 2. Bandwidth was increased to 1395 Hz/pixel,
base matrix of 256 pixels, flip angle 35°, FoV 400 mm, TR
= 3.9 ms, TE = 1.14 ms, voxel size 2.1 x 1.4 x 10 mm. Mo-
tion correction was used on all sequences. T1 maps were
generated by the scanner at 1.5T and 3T.
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T2* quantification
The myocardial T2* quantification with truncation has
been described elsewhere [7]. In brief, dedicated software
was used (Thalassaemia tools, a plug-in of CMRtools,
Cardiovascular Imaging Solutions, London). The entire
thickness of the cardiac interventricular septum was
delineated to measure signal intensity (SI) decay at each
echo time. The SI was subsequently plotted against echo
time and a mono-exponential trendline was fitted to the
decay curve to derive T2* according to this equation:
SI ¼ SI0 :e–TE=T2
T2* was subsequently transformed into its reciprocal
R2* according to the equation:
T2 ¼ 1000=R2
Curve fitting was performed with the truncation method
[24]. The conventional T2* cut-off value for the presence
of significant cardiac iron overload at 1.5T of 20 ms was
used [7].
Native T1 quantification
An identical mid-ventricular septum region of interest
(ROI) was used for T1 quantification. Delineation of the
epicardial and endocardial borders was done on the T1
maps. The interventricular septum was subsequently
isolated for quantification. Careful consideration was
given not to include blood-pool or artefacts in the septal
ROI. T1 maps were automatically derived as described
previously, [25–27] by fitting the measured signals to the
following equation:
SI TIð Þ ¼ A − B:e− TI=T1ð Þ
Where SI is the signal intensity at a specific inversion
time (TI), and T1 can be approximated:
T1 ≈ T1  B=A – 1ð Þ:
When required, T1 was subsequently transformed into
its reciprocal R1 using a similar equation:
T1 ¼ 1000=R1
No gadolinium contrast agent was administered. A single,
blinded, experienced observer performed analysis for BB
T2* at 1.5T, and MOLLI T1 at 1.5T and 3T.
Reproducibility
A group of 20 patients was randomly selected for inter-
observer, intra-observer and inter-study variability measure-
ments. These patients had levels of myocardial siderosis
that covered the entire range of the disease (from absent to
severe iron overload). For intra-observer variability, the
same investigator blindly reassessed myocardial T1 and T2*
on 2 occasions a month apart. For inter-observer variability,
two highly experienced investigators separately and blindly
reported T1 and T2* for each patient. Finally, these 20 pa-
tients underwent a repeated cardiac T1 scan at 1.5T and at
3T one hour after completing the previous scan. The same
investigator randomly and blindly re-evaluated T1 in these
subjects to obtain inter-study variability.
Statistical analysis
Data are expressed as median (interquartile range), except
where stated as being the median and full range of values.
Comparison of T2* and T1 values between normal volun-
teers and iron overload patients was performed with
Mann–Whitney U test. Association between T2*, T1, R2*
and R1 values at different field strengths were evaluated
with a linear or non-linear regression when appropriate.
Coefficients of variation (CoV) and intra-class correlation
(ICC) with 95 % confidence interval (CI) analysis were
conducted to assess inter- and intra-observer variability
in addition to inter-study variability of T1 values. For
ICC, an alpha two-way mixed model with absolute
agreement analysis was used. Finally, Bland-Altman
plots were generated to further describe the reproduci-
bility of T1 measurements at 1.5T and at 3T [28]. A P-
value <0.05 was considered significant. All analyses
were done using SPSS software version 22.0.0, IBM,
Chicago, Illinois, USA.
Results
Patient characteristics and comparison with healthy
volunteers
A cohort of 53 iron overload patients and 20 healthy vol-
unteers were included. Their demographics and clinical
characteristics are shown in Table 1 and typical images
from a single patient are shown in Fig. 1. The median age
of the patients was 35 (24–59) years old. The largest pro-
portion of patients had β-thalassaemia (n = 22, 42 %). Me-
dian left ventricular ejection fraction by CMR was 64 %
(59–67). Four patients did not undergo T1 quantification
at 1.5T because of software issues on the scanner. In two
of the patients with severe cardiac iron overload, T1 at
1.5T was not available. All patients underwent T1 quanti-
fication at 3T.
In the normal volunteers control group, the median
T1 at 1.5T was 1014 ms [974–1033] and the full range
of values was 939–1059 ms. In accord with previous
intellectual considerations defining the lower limit of
normal of T2* to represent the onset of significant
iron loading, so that low values should rarely be seen
in the normal population, we used the lowest T1 observed
in normals of 939 ms at 1.5T as the lower limit of normality
for the scanner and sequence that was used in this report.
The median T1 at 3T was longer at 1165 ms [1119–1194]
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and the full range of values was 1056–1224 ms. Using the
same argument as above, we therefore set the lower limit of
normal for significant iron loading as being the lower limit
of the normal range at 3T which was 1056 ms.
Association between T1 and T2* both at 1.5T
The relation between T1 and T2* at 1.5T is shown in
Fig. 2a. A power regression model was fitted to the data
yielding an equation of y = 377 · x0.282 (R2 = 0.717). All
patients with cardiac iron overload (T2* <20 ms at 1.5T)
had T1 values at 1.5T below the lower limit of normal
T1 values in the control cohort (939 ms). Only four pa-
tients had T2* values >20 ms at 1.5T and had T1 values
at 1.5T below the lower limit of T1 values found in the
present normal cohort. As shown in Fig. 2b, the relation
between R1 and R2* at 1.5T was linear (y = 0.007 · x +
0.794; R2 = 0.772).
Association between T1 at 3T and T2* at 1.5T
The relation between T1 at 3T and T2* at 1.5T is shown
in Fig. 3a, and described by the power model regression
with fit y = 406 · x0.294 (R2 = 0.715). All patients with a
significant degree of iron overload (T2* <20 ms at 1.5T)
had a T1 values at 3T <1056 ms (lower threshold of the
normal volunteers). A total of seven patients with nor-
mal T2* values at 1.5T had T1 values below 1056 ms at
3T. The association between R1 at 3T and R2* at 1.5T is
shown in Fig. 3b. The power regression equation for this
relation was y = 0.324 · x0.293 (R2 = 0.715).
Reproducibility
The intra-observer, inter-observer and inter-study variabil-
ity of T1 at 1.5T and at 3T is shown in Table 2. There was
Table 1 Patient characteristics
Variables Patients N = 53 Controls N = 20 P-value
Age (years) 35 [24–59] 34 [25–41] 0.45
Gender (Male/Female) 33/20 9/11 0.20
Diagnosis
TM 22
SCA 9
Rare hemoglobinopathies 15
MDS 4
Other 3
LVEF (%) 64 [59–67]
Myocardial T2* (ms) at 1.5T 28.1 [20.4–34.4] 30.8 [29.0–34.4] 0.14
Full range 6.41–41.5 22.6–40.4
Myocardial T1 (ms) at 1.5T 978 [865–1039] 1014 [974–1033] 0.21
Full range 661–1084 939–1059
Myocardial T1 (ms) at 3T 1103 [927–1148] 1165 [1119–1194] 0.001
Full range 653–1222 1056–1224
Data are expressed as median [interquartile range]. LVEF left ventricular
ejection fraction, MDS, myelodysplasic syndrome, SCA sickle cell anemia,
TM thalassemia major
Fig. 1 Example images from a single patient with iron overload:
a Black blood T2* at 1.5T is reduced at 13.7 ms, indicating mild to
moderate iron loading; b MOLLI T1 at 1.5T is reduced at 661 ms;
c MOLLI T1 at 3T is longer than at 1.5T but still reduced at 747 ms
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excellent agreement between the repeated measurements
of T1 at both 1.5 and 3T, but the most important measure
of inter-study variability of T1 was better at 3T than 1.5T.
The Bland-Altman plots confirm that there was no sys-
temic bias in reproducibility of T1 at 1.5T (Fig. 4) and at
3T (Fig. 5). The T1 reproducibility for all measures at both
1.5T and 3T appeared superior to T2* at 1.5T.
Discussion
These data show reasonable correlations between cardiac
T1 and cardiac T2* measures across a wide range of car-
diac iron loading, but with significant scatter, and there is
reasonable agreement with our previous data comparing
T1 and T2* at 1.5T in thalassaemia patients, [23] and with
the more recent data from Sado et al., [29] although with
Fig. 2 a Association between T1 at 1.5T and T2* at 1.5T; b Association between cardiac R1 at 1.5T and R2* at 1.5T
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differences as discussed below. There is a prima facie case
therefore for supporting the notion that T1 has a potential
role in iron measurement. The question that arises is what
might be the relative advantages and disadvantages for
using T1.
The advantages of T1 CMR include: A) At low iron
levels, T1 is less affected by non-iron influences that
affect T2* measurements, making T1 appear to be more
suitable for clinical conditions where low iron levels may
be responsible for disease pathogenesis; B) T1 has good
inter-study reproducibility, which appears superior to
T2* which may be of benefit for longitudinal patient
follow-up and clinical trials. Counterbalancing views
to these advantages are: A) The dominant pathologies
Fig. 3 a Association between T1 at 3T and T2* at 1.5T; b Association between R1 at 3T and T2* at 1.5T
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associated with iron dysfunction by prevalence are those in-
volving substantial iron overload (eg transfusion dependent
anaemias, haemochromatosis) and for these conditions
there is rather little obvious merit in defining iron levels
moving within the non-significant range, when movements
of T2* are robustly identifiable in the low-risk mild to
moderate iron overload range of cardiac T2* between
10–20 ms. Nonetheless, some more unusual pathologies
are apparently associated with iron dysfunction at low iron
levels, [23, 30] for which T1 might be a more suitable iron
assay than T2*. B) The improved inter-study reproducibil-
ity of T1 measurements is potentially valuable. This being
said, it is clear that the performance of cardiac T2* could
hardly be described as weak. The relative CoV’s at 1.5T for
T1 and T2* in this paper were 1.79 % vs 4.55 % with near
identical ICCs of 0.993 vs 0.994. Both parameters there-
fore appear to be strong performers in absolute terms.
Certainly sample sizes in the order of 60 have been used
in randomised controlled trials using T2* as the primary
endpoint, that showed a significant difference between the
performance of competing iron chelators, [31, 32] and a
sample size of less than this may not be clinically credible.
However, T1 might have an advantage if 2 drugs with
similar efficacy were to be compared. This would depend
on other factors as well, including standardisation of T1
measurements, as addressed further below. It should be
noted that improvements in T2* technology may improve
reproducibility [33].
It has also been suggested that cardiac T1 might have
improved utility for identifying patients with cardiac iron
loading through a better delineation of the lower limit of
normal for cardiac iron loading [29]. It is difficult to
sympathise with this view. The normal range for cardiac
iron has received rather little scientific attention from
basic science, with the most commonly cited paper from
Collins and Taylor published in 1987 indicating a normal
range in eight hearts of 0.34 mg/g dw (range 0.29–0.47)
[34]. From the work of Carpenter et al., [6] the accepted
mean normal myocardial T2* value of 40 ms yields a
myocardial iron concentration of 0.5 mg/g dw which is
in reasonable accord with this upper range. It is remark-
able that such a level of agreement should occur given
that the methodologies of myocardial iron measurement
are completely different and performed some 24 years
apart, and does lend credence to the T2* calibration. The
definition of the normal range of cardiac iron from T2*
is however philosophically challenging. Early attempts
Table 2 Reproducibility of myocardial T1 at 1.5T and 3T, and
T2*at 1.5T
Myocardial T1 1.5T 3T
Intraobserver CoV (%) 0.56 0.84
ICC (95 % CI) 0.999 (0.998–1.000) 0.999 (0.997–0.999)
Interobserver CoV (%) 0.98 0.89
ICC (95 % CI) 0.998 (0.995–0.999) 0.996 (0.988–0.999)
Interstudy CoV (%) 1.79 1.45
ICC (95 % CI) 0.993 (0.982–0.997) 0.996 (0.989–0.998)
Myocardial T2*
Intraobserver CoV (%) 1.54
ICC (95 % CI) 1.000 (1.000–1.000)
Interobserver CoV (%) 2.76
ICC (95 % CI) 0.999 (0.999–1.000)
Interstudy CoV (%) 4.55
ICC (95 % CI) 0.994 (0.985–0.998)
Abbreviations: CI confidence interval, CoV coefficients of variation, ICC intraclass
correlation coefficient
Fig. 4 Bland Altman plots for T1 reproducibility at 1.5T a intra-observer;
b inter-observer; c inter-study reproducibility
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to justify the lower limit of normal were made on the
simple basis of taking the mean measurement in nor-
mals and subtracting two standard deviations. However,
it is now known that T2* is not normally distributed
and this approach which leaves the lower ~5 % of the
normal population with “cardiac iron overload” is neither
sensible statistically nor satisfying clinically. A more prag-
matic approach is to sample a normal population and take
the lowest T2* value obtained as the lower threshold (as-
suming that the normal population does not include a
subject with occult iron loading). For myocardial T2*, this
has generally been accepted as 20 ms, although other
values can and have been suggested. A further persuasive
argument for definition of a normal range is to associate
the T2* to outcomes, because this is patient focussed
rather than test focussed. The work from Kirk et al.
clearly showed that heart failure occurs in a very high
proportion of cases only when myocardial T2* <10 ms
(myocardial iron equivalent of 2.7 mg/g dw). This
threshold of severe iron loading is therefore beyond
question. However, it is clear that to suggest that there
needs a hard and fast rule to define the threshold for
the onset of mild cardiac iron overload is somewhat
misguided and unhelpful. Since the range of myocardial
T2* between 20 ms and 10 ms is large and easily mea-
sured, it serves as a valuable early warning zone that
problems are likely in the future should the T2* drop
further. Whether this range starts at 20 ms or at a slightly
higher value takes no account of the continuous nature of
iron loading and suggests a vital clinical importance for
decision making based on an arbitrary threshold, which is
not the case. It is therefore possible to consider that ques-
tions of whether T1 or T2* better identify a threshold for
early cardiac iron loading are moot. The position that T1
is better for identifying the lower limit of normal for myo-
cardial T1 is also problematic unless the measurement can
be standardised, with for example Sado et al. reporting a
value of 904 ms (Sado et al. [29]) vs 939 ms in this report.
Another potential advantage of T1 measurement of
iron concentration which is identified in this paper, is
the use of T1 at 3T. There has been substantial increase
in the use of 3T for MR of the brain and musculoskeletal
system, and a number of centres no longer have 1.5T
scanners available causing problems for thalassaemia pa-
tients. The two most likely solutions to this problem are
to calibrate T2* at 3T against 1.5T, on which progress
has already been made, [14, 15, 35] or to consider using
T2 or T1 mapping. In this paper, we show that T1 map-
ping at 3T is feasible and causes only rather modest pro-
longation of T1 values (median normal at 1.5T vs 3T:
1014 ms vs 1165 ms). The scatter of T1 vs T2* values at
3T (Fig. 3a) is similar to that at 1.5T (Fig. 2a) and the
inter-study reproducibility of T1 at 3T (1.45 %) was
slightly superior to 1.5T (1.79 %). This approach may be
worth exploring further, because T2* imaging at 3T has
increased artefacts and shorter T2* values, which can be
problematic to image compared with imaging at 1.5T.
A problem associated with the current implementation
of T1 mapping is the variation of absolute values of T1
between sequences and scanners. This is illustrated in
this paper where the median value of T1 at 1.5T in normal
subjects was 1014 ms which compares with the mean of
968 ms from Sado et al. [29] Sado used the shortened
form of MOLLI (shMOLLI) as well as MOLLI and they
found a 25 ms difference between their techniques [29].
This difference is not insignificant, being almost one
standard deviation in their normal range (32 ms). These
differences arise from the complex nature of measuring
T1, which is affected by which sequence is used, [36] and
Fig. 5 Bland Altman plot for T1 reproducibility at 3T a intra-observer;
b inter-observer; c inter-study reproducibility
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a large number of technical parameters that are difficult to
standardise [27]. Work is ongoing to try to resolve these
issues, [37, 38] but T1 mapping for iron assessment would
currently require each centre to establish its own normal
range. This issue for T1 is less problematic for marked
iron loading however, because the dynamic range of decre-
ment in T1 reaches ~300 ms, although the direct compari-
son of T1 values between centres would remain difficult.
It is also clear that the direct comparison of T1 against
T2* values which are understood clinically, relies consider-
ably on the modelling used to relate these 2 parameters,
and this is currently unresolved. The three papers that
have modelled T1 against T2* at 1.5T have found signifi-
cantly different regression lines due to data scatter, such
that for example, a T2* of 10 ms approximates to a T1 of
620 ms by Feng et al., [23] 650 ms by Sado et al., [29] and
720 ms in the current paper. This situation is different to
that faced by T2*, which proved straightforward to trans-
fer between centres, [10] between different manufacturers’
scanners, [39, 40] and between centres internationally,
[11, 39] yielding excellent intercenter agreements of T2*
values at an early stage of development [11, 39].
Some further technical issues need to be considered in
the use of T1 for iron assessment. Diffuse fibrosis raises
native T1, whereas myocardial iron lowers native T1. There
is debate about the prevalence of myocardial fibrosis in
thalassaemia, [41, 42] but its occurrence would increase the
T1 value causing iron underestimation. T2* does not
appear to be significantly affected by myocardial fibrosis
[43, 44]. A further confounding issue for T1 measure-
ments is that with increasing iron loading, T2* effects
influence the measurement of T1, [16, 23] which affects
its accuracy. T1 measurements need to be performed on
carefully selected regions of interest in the myocardium
that exclude other tissues with very different T1, such as
blood and fat, to prevent erroneous T1 values [45]. Fi-
nally, there is a report that T1 varies by gender and age,
with increased values by 24 ms in females up to the age
of 45 years, [45] which would be unwelcome if substanti-
ated. All these issues need further consideration.
Further issues with the validation of T1 also exist, that
are troublesome. Clearly this paper and others have shown
that T1 can be used to measure tissue iron concentration,
but in humans the only comprehensive validation in the
heart has been performed using T2*. Myocardial T2* mea-
sured at 1.5T is firmly established as the gold standard
measurement of myocardial iron concentration, [12] and
this is because of a number of important reasons: 1) The
scan is fast (short single breath-hold) which makes it easy
for patients to tolerate (even children) and therefore effi-
cient on time use of the MR scanner; 2) It is robust in
clinical practice and scan failures are unusual; 3) Absolute
T2* values are highly reproducible between different man-
ufacturers scanners and sequences allowing individual
centres to directly compare patients’ results; [39] 4) The
inter-study reproducibility is very good allowing small
sample sizes for clinical treatment studies in the order of
60 patients; 5) The T2* technique is calibrated directly to
human heart tissue, [6, 9] but attempts to calibrate T1
against human heart tissue have to date failed, [46] as a
result of the effects of formalin on T1 relaxation. 6)
The relation between cardiac T2* value and future cardiac
events is well described and powerful; [5] 7) The technique
is widely disseminated in clinical practice around the world,
[47] which is not the case for T1; 8) And a reduction in car-
diac mortality has been demonstrated using T2* as a guide
to aggressive iron chelation therapy that is tailored to the
heart in advance of the onset of heart failure [13]. Therefore
any MR scanning alternative to T2* has a substantial bur-
den of re-validation and outcomes analysis to climb to
reach the same level of clinical confidence in use. Another
approach to this problem is simply to assume that putative
alternatives such as T1 would simply be calibrated against
conventional T2* values at 1.5T and therefore directly
cross-referenced to the established cardiac T2* literature.
Such an approach has merit, but certainly leaves room for
doubt as to veracity of the measurement, because there is
no guarantee that T1 and T2* measure identical chemical
iron species with identical effects on outcome. The
additional problem already mentioned is that there are
significant problems in identifying the best fit curve be-
tween T1 and T2* which leads to uncertainty.
Conclusions
Native T1 mapping at 1.5T appears to be promising as a
tool to evaluate myocardial iron. However, considerable
further work is required in standardisation and transfer-
ability between scanners and centres, as well as in un-
derstanding whether T1 can be used as a substitute for
T2* in the absence of direct studies of calibration and
linkage with cardiovascular outcomes. The established
practice worldwide of using T2* at 1.5T is unlikely to
change in the near future without persuasive additional
arguments. However, T1 measurements at 3T may prove
useful where T2* measurements can be problematic.
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